Project Grant R01HL184124
Award Date 5/1/26
Completion Date 2/28/31
Dollars Obligated $868K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $106,391 Project Grant to the University of Colorado-Denver on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research examining the role of developmental dysanapsis in lung development throughout the lifespan in experimental bronchopulmonary dysplasia (BPD). The research will be conducted in Colorado and is scheduled for completion by August 31, 2027. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $427,256 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to Columbia University's Health Sciences Division on September 15, 2025, to conduct a pilot feasibility study supporting development of a definitive randomized controlled trial evaluating bilevel positive airway pressure (BPAP) as a second-line therapy for severe pediatric asthma exacerbations in emergency department settings. The...
- Federal Project Grant Award Summary The University of Pennsylvania received a $629,498 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of June 30, 2030. This project deliverable focuses on deciphering the molecular mechanisms of pediatric interstitial lung disease (CHILD), a rare and progressive lung disease caused by mutations in the surfactant...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $156,168 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center for research exploring the role of the Hedgehog pathway-primary cilia axis in human lung alveolarization and disease under the Cardiovascular Diseases Research program (CFDA 93.837). The two-year project, initiated August 1, 2025 and concluding July 31, 2027, investigates how hedgehog signaling regulates alveolar...
- Federal Grant Award Summary The University of Pittsburgh received a $258,516 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025 through June 30, 2027. This award funds research investigating mitochondrial-derived peptides (MDPs) in chronic obstructive pulmonary disease (COPD), a condition affecting approximately 16 million U.S. adults and representing the sixth leading cause of death...
- Federal Grant Award Summary The University of Pennsylvania received a $1,351,359 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2025, through March 31, 2030. This research project investigates alveolar epithelial stress signaling mechanisms in pulmonary fibrosis, a progressive and devastating lung disease with limited therapeutic options. The research will elucidate how aberrant alveolar...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1.15 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning March 1, 2026, and extending through January 31, 2033. This research initiative aims to regenerate lung tissue through enhanced understanding of epithelial development and regeneration, with particular focus on addressing end-stage lung diseases such...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $744,880 to the University of Colorado-Denver through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a four-year research project running from September 1, 2025, through May 31, 2029. The research investigates epimetabolic regulation of macrophage activation during acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), focusing on how lactate produced by...
- Federal Grant Award Summary The University of Pennsylvania received a $782,473 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025, and completion target of July 31, 2029. This research project aims to improve understanding of obstructive sleep apnea (OSA) pathogenesis through the application of novel imaging techniques during sleep. The research will combine...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...